BPC-157 vs GHK-Cu for dogs

BPC-157

BPC-157 has the most directly relevant safety data of any compound on this site as it applies to dogs. A dedicated preclinical toxicity evaluation covering mice, rats, rabbits and dogs reported that it was well tolerated with no serious toxicity, no genotoxicity and no embryo-fetal toxicity; the single notable finding was a decrease in creatinine at 2 mg/kg, which resolved spontaneously after two weeks of withdrawal and did not occur at lower doses. Local irritation was mild. The meaningful caveat is duration rather than dose — those studies covered single and repeated dosing, not months of continuous administration.

GHK-Cu

GHK-Cu used topically is among the lowest-risk options on this site — systemic absorption is minimal and long-term use is generally considered acceptable. Note that despite frequent claims otherwise, there is no canine study behind it: the often-cited Veterinary Surgery paper was conducted in rats. The injectable route carries a genuine, breed-specific hazard: Bedlington Terriers and some Labrador lines carry inherited copper storage disease, and any dog with hepatic impairment handles copper poorly. Baseline and follow-up liver values are the safeguard, and for localised problems the topical route usually makes the injectable question moot.